Hirschsprung's disease (HSCR), a frequent developmental defect of the enteric nervous system is due to lossof-function mutations of RET, a receptor tyrosine kinase essential for the mediation of glial cell-derived neurotrophic factor (GDNF)-induced cell survival. Instead, gain-of-function Cys mutations (e.g., Cys 609 , Cys 620 , and Cys 634 ) of the same gene are responsible for thyroid carcinoma (MEN2A/familial medullary thyroid carcinoma) by causing a covalent Ret dimerization, leading to ligand-independent activation of its tyrosine kinase. In this context, the association of Cys 609 -or Cys 620 -activating mutations with HSCR is still an unresolved paradox. To address this issue, we have compared these two mutants with the Cys 634 Ret variant, which has never been associated with HSCR, for their ability to rescue neuroectodermic cells (SK-N-MC cells) from apoptosis. We show here that despite their constitutively activated kinase, the mere expression of these three mutants does not allow cell rescue. Instead, we demonstrate that like the wild-type Ret, the Cys 634 Ret variant can trigger antiapoptotic pathways only in response to GDNF. In contrast, Cys 609 or Cys 620 mutations, which impair the terminal Ret glycosylation required for its insertion at the plasma membrane, abrogate GDNFinduced cell rescue. Taken together, these data support the idea that sensitivity to GDNF is the mandatory condition, even for constitutively activated Ret mutants, to rescue neuroectodermic cells from apoptosis. These findings may help clarify how a gain-of-function mutation can be associated with a developmental defect.The RET receptor tyrosine kinase (RTK) provides one of most interesting and documented models of human diseases caused by mutations within a single gene (for a review see reference 37). Its germ line mutations have been associated with Hirschsprung's disease (HSCR), a frequent defect (1 in 5,000 births) of development of the enteric nervous system (ENS) characterized by aganglionosis of the distal digestive tract. RET mutations are also involved in tumor formation: somatic RET chromosomal rearrangements are implicated in papillary thyroid carcinoma, and germ line RET mutations are responsible for the development of three inherited endocrine carcinomas: Familial medullary thyroid carcinoma (FMTC) and multiple endocrine neoplasia types 2A (MEN2A) and 2B (MEN2B).Detailed biochemical analysis of RET mutations in the MEN2A/FMTC and HSCR families has shown how different mutations can lead to such opposite diseases. Indeed, RET encodes an RTK, expressed in tissues derived from the neural crest such as ENS, thyroid, and adrenal medulla (34, 54).